Pharmacist Group Has “Serious” Concerns With Biosimilar Bills

State-level efforts to hinder substitution of biosimilar interchangeable products are premature and unfounded, a U.S. pharmacist group says, as Oregon and Delaware join a growing list of states moving to advance legislation that restricts the substitution of biosimilars for brand biologics.
Washington Drug Letter